EDP239
CEDP239X2201
Phase 1 small_molecule completed
Quick answer
EDP239 for Hepatitis C is a Phase 1 program (small_molecule) at ENANTA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ENANTA PHARMACEUTICALS INC
- Indication
- Hepatitis C
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed